Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Depreciation & Amortization (CF): 2018-2025

Historic Depreciation & Amortization (CF) for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to $800,000.

  • Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) fell 11.11% to $800,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 9.60%. This contributed to the annual value of $3.5 million for FY2024, which is 18.13% up from last year.
  • Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) amounted to $800,000 in Q3 2025, which was down 0.00% from $800,000 recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) ranged from a high of $904,000 in Q1 2024 and a low of $224,000 during Q1 2022.
  • In the last 3 years, Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) had a median value of $801,000 in 2025 and averaged $807,455.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first fell by 27.04% in 2022, then soared by 167.86% in 2023.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) stood at $300,000 in 2021, then skyrocketed by 75.67% to $527,000 in 2022, then spiked by 62.81% to $858,000 in 2023, then dropped by 4.55% to $819,000 in 2024, then decreased by 11.11% to $800,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $800,000 for Q3 2025, versus $800,000 for Q2 2025 and $801,000 for Q1 2025.